Regulated Information
Financial Reports
SEC Filings
Filter
6-K
Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition
6-K
Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate
6-K
Celyad Oncology Announces $32.5 Million Private Placement With Fortress Investment Group
6-K
Celyad Oncology Presents Preclinical Data On Allogeneic CAR T Therapy Program And Highlights KEYNOTE-B79 Clinical Trial Design At The Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting
6-K
Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights